“OUTCOMES OF SUBSEQUENT TREATMENT AFTER ATEZOLIZUMAB–BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA” (2026) Vietnam Journal of Community Medicine, 67(10). doi:10.52163/yhc.v67i10.6872.